Jan 26 2026 University of California San Diego-led team has discovered that restoring a key cardiac protein called connexin‑43 in a mouse model can dramatically improve heart function and extend survival in several inherited forms of arrhythmogenic cardiomyopathy (ACM). The research suggests that a single gene therapy might someday help a wide range of ACM … Read more
Genetic testing in patients with atrial fibrillation (AF) may identify those at higher risk of developing incident cardiomyopathy or heart failure, new research from the Netherlands suggested. In a study that included two longitudinal cohorts (the All of Us Research program and the UK Biobank), the prevalence of inherited rare gene variants associated with cardiomyopathy … Read more
During a recent webinar hosted by the Scientific Society of General Medicine, Christophe Scavée, MD, head of the Department of Cardiology and Rhythmology Unit at Cliniques Universitaires Saint-Luc, Brussels, Belgium, discussed the critical role that general practitioners (GPs) play in sports screening. He outlined the essential steps GPs should take when patients want to start … Read more
New clinical guidance to help cardiologists navigate the complexity of cardiogenic shock and assess possible cases within the first hour after onset introduces a memory aid — SUSPECT — which stands for symptoms/signs, urine output, sustained hypotension, perfusion, electrocardiogram/echocardiogram, congestion, and triage. The guidance is the first in a planned series from the American College … Read more
TOPLINE: A 12-week supervised high-intensity exercise programme was feasible for patients with hypertrophic cardiomyopathy (HCM), leading to potential improvements in cardiorespiratory fitness, cardiovascular risk factors, and psychological outcomes, without an increased risk for arrhythmias. METHODOLOGY: This study examined the feasibility and impact of an individualised high-intensity exercise programme in patients with HCM recruited at three … Read more
Tirzepatide Shows Promise in Reducing cardiovascular Risk for Obese heart Failure Patients A new analysis of the SUMMIT trial reveals that the glucagon-like peptide 1 (GLP-1) agonist tirzepatide significantly lowers the risk of cardiovascular (CV) events in patients with obesity and heart failure with preserved ejection fraction (HFpEF). This benefit remains consistent nonetheless of whether … Read more
The glucagon-like peptide 1 (GLP-1) agonist tirzepatide lowers the risk for cardiovascular (CV) events in patients with obesity and heart failure with preserved ejection fraction (HFpEF), whether they have general adiposity, measured with the body mass index (BMI), or central adiposity, measured with the waist-to-height ratio, showed a new analysis from the SUMMIT trial. This … Read more
A research team co-led by scientists at the University of Arizona College of Medicine – Tucson found that an osteoporosis drug might counter a rare genetic mutation underlying a type of heart disease. The results were published today in the Journal of Clinical Investigation and could have implications for treating other rare diseases. Dilated cardiomyopathy is a group of … Read more
This story has been made freely available as a public service to our readers. Please consider supporting SCMP’s journalism by subscribing. The parents of a seven-month-old Hong Kong baby girl in need of a life-saving heart transplant have appealed again for a suitable donor as she suffers from worsening respiratory failure. Hong Kong Children’s Hospital … Read more
The most common cardiovascular killer in maternal medicine is also among the most misdiagnosed. Peripartum cardiomyopathy (PPCM), a systolic dysfunction that occurs either in late pregnancy or in the early postpartum stage, is often misdiagnosed in the obstetric and primary care settings, according to experts. “I’ve looked at why people die during pregnancy and postpartum, … Read more